Raxibacumab

BIOLOGICAL3 trials

Sponsors

Human Genome Sciences Inc., Emergent BioSolutions

Conditions

HealthyInfections, BacterialTherapeutic Treatment of Inhalation Anthrax

Phase 2

An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

CompletedNCT02016963

Human Genome Sciences Inc.Therapeutic Treatment of Inhalation Anthrax

Start: 2008-01-31End: 2008-05-31Updated: 2018-11-29

Phase 3

A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects

CompletedNCT00639678

Human Genome Sciences Inc.Healthy

Start: 2008-03-31End: 2008-09-30Updated: 2018-11-15

Phase 4

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

CompletedNCT02339155

Emergent BioSolutionsInfections, Bacterial

Start: 2015-02-24End: 2017-06-06Updated: 2024-03-18

Related Papers

Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.

2020-04-2212 citations

Raxibacumab for the treatment of inhalational anthrax.

2009-07-01200 citations